Delving into the Latest Updates on Diethylcarbamazine Citrate with Synapse

Veterinary drugs are widely used to treat livestock diseases, but the emergence of problems related to drug resistance prompted the government of the Republic of Korea to enact laws regulating the use of veterinary drugs in livestock.Monitoring the contents of residual drugs in livestock products at regular intervals is necessary to assess whether the regulations have resulted in the effective management of food product safety and prevent and manage unexpected problems related to this issue.A 2019-2023 livestock product post-marketing monitoring program launched by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea inspected 1135 livestock products.Sixty-two different veterinary drugs were detected among 167 monitored, with a detection rate of 28.2% (320/1135 samples; chicken [125], pork [114], milk [35], beef [30], and egg [16]).Diclazuril was detected most frequently, followed by flumequine, clopidol, and enrofloxacin.Over the past five years, two samples that did not conform to the regulations were identified to contain 20 and 215 ng/g, diclazuril and toltrazuril sulfone, resp.The estimation of exposure and risk assessment revealed that the hazard index of diclazuril was below 75%.However, in case of toltrazuril sulfone, it showed a hazard index exceeding 138% in the scenario of the 95th percentile high consumption of chicken.The results of this study may provide a useful reference in initiating more targeted work in the future, such as the further fine-tuning of food safety monitoring programs and developing food safety standardsIn future studies, the MFDS shall continue to monitor the statuses of residual veterinary drugs in com. livestock products.

01 Dec 2024·Molecular biology reports

Detection of Wuchereria bancrofti DNA in wild caught vector and non-vector mosquitoes: implications for elimination of lymphatic filariasis

Article

Author: Hoti, Sugeerappa Laxmanappa ; Venkatesan, Vasuki ; Adinarayanan, Srividya ; Abraham, Philip Raj ; Kumar, Ashwani ; Raju, Konuganti Hari Kishan ; Swaminathan, Subramanian ; Ramalingam, Balasubramaniyan

BACKGROUND:

Transmission Assessment Survey (TAS) is the WHO recommended method used for decision-making to stop or continue the MDA in lymphatic filariasis (LF) elimination programme. The WHO has also recommended Molecular Xenomonitoring (MX) of LF infection in vectors as an adjunct tool in settings under post-MDA or validation period. Screening of non-vectors by MX in post-MDA / validation settings could be useful to prevent a resurgence of LF infection, as there might be low abundance of vectors, especially in some seasons. In this study, we investigated the presence of LF infection in non-vectors in an area endemic for LF and has undergone many rounds of annual MDA with two drugs (Diethylcarbamazine and Albendazole, DA) and two rounds of triple drug regimens (Ivermectin + DA).

METHODS AND RESULTS:

Mosquitoes were collected from selected villages of Yadgir district in Karnataka state, India, during 2019. A total of 680 female mosquitoes were collected, identified morphologically by species and separated as pools. The female mosquitoes belonging to 3 species viz., Anopheles subpictus, Culex gelidus and Culex quinquefaciatus were separated, pooled, and the DNA extracted using less expensive method and followed by LDR based real-time PCR assay for detecting Wuchereria bancrofti infection in vector as well as non-vector mosquitoes. One pool out of 6 pools of An. subpictus, 2 pools out of 6 pools of Cx. gelidus, and 4 pools out of 8 pools of Cx. quinquefaciatus were found to be positive for W. bancrofti infection by RT-PCR. The infection rate in vectors and non-vectors was found to be 1.8% (95% CI: 0.5-4.2%) and 0.9% (95% CI: 0.2-2.3%), respectively.

CONCLUSIONS:

Our study showed that non-vectors also harbour W. bancrofti, thus opening an opportunity of using these mosquitoes as surrogate vectors for assessing risk of transmission to humans in LF endemic and post MDA areas.

01 Dec 2024·JOURNAL OF HAZARDOUS MATERIALS

N-coordinated iron sites dispersed in porous carbon frameworks to activate peroxymonosulfate for efficient sulfisoxazole degradation and real hospital wastewater decontamination

Article

Author: Gu, Lingyun ; Long, Quan ; Wu, Zelin ; Yu, Chunxiu ; Wu, Yi ; Zhang, Li ; Chen, Kexin ; Shi, Hongle ; Xiong, Zhaokun ; Lai, Bo

Herein, an N-coordinated Fe site dispersed in porous carbon frameworks (Fe-NC) fabricated from zeolitic imidazolate frameworks encapsulated with iron acetylacetonate (Fe(acac)₃ @ZIFs) was employed to activate peroxymonosulfate (PMS) for the attenuation of sulfisoxazole (SIZ) and treating real hospital wastewater. The constructed Fe-NC/PMS system exhibited good catalytic stability for SIZ degradation, maintaining excellent degradation performance over multiple cycles with virtually no leaching. The quenching experiments, electron paramagnetic resonance (EPR) capture analyses, and semi-quantitative measurements showed that singlet oxygen (¹O₂) and high-valent metal-oxo species were mainly responsible for SIZ degradation by Fe-NC/PMS. Significantly, ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS) was used to trace 134 pharmaceutical contaminants in real hospital wastewater. Effective degradation was achieved for 87 % of the pharmaceutical contaminants by the Fe-NC/PMS process. Seventy-four pharmaceutical contaminants were eliminated. Taken together, this work successfully established the Fe-NC/PMS technology using the developed iron-based materials and explored its application to real hospital wastewater treatment, providing an eco-friendly and effective strategy for treating wastewater.

100 Deals associated with Diethylcarbamazine Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00803	Diethylcarbamazine Citrate	P02CB02	DB00711

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Filariasis	JP	Mitsubishi Tanabe Pharma Corp.	01 Feb 1951
Elephantiasis, Filarial	US	Lederle Laboratories	13 Nov 1950

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04188301 (DOLF IDA/Oncho, CTgov)	Phase 2	Onchocerciasis	154	Albendazole+Ivermectin (IVM + ALB)	trlhcilpaf(dsdnkkdcnv) = dgawdheanj iplpwhbnyw (ncosngdjem, mbuqddjmsz - lonunqlgwl) View more	-	10 May 2023
				albendazole+ivermectin+diethylcarbamazine (IDA x 1 Dose)	trlhcilpaf(dsdnkkdcnv) = getuvhsxfl iplpwhbnyw (ncosngdjem, qkhqedghtz - qxghbqbihs) View more
NCT03177993 (Pubmed \| Clin Infect Dis)	Not Applicable	Elephantiasis, Filarial	3,816	Ivermectin, diethylcarbamazine, and albendazole	nyykvgbibw(trxzpfkpsv) = urozpaotnk nkpmyumybj (iaghzrvcce, 43.6 - 78.2)	-	17 Mar 2021
				Diethylcarbamazine and albendazole	nyykvgbibw(trxzpfkpsv) = mpyojytrch nkpmyumybj (iaghzrvcce, 57.2 - 79.1)
NCT02974049 (Pubmed \| Clin Infect Dis)	Not Applicable	Elephantiasis, Filarial	95	Single dose of IDA (ivermectin plus diethylcarbamazine plus albendazole)	pnetafglso(ufcsbltpzz) = yrnfsnhfxf jhqlqialue (stdlvicipq, 56 - 85) View more	Positive	23 Oct 2019
				Three annual doses of IA (ivermectin plus albendazole)	pnetafglso(ufcsbltpzz) = keolwyucgh jhqlqialue (stdlvicipq, 14 - 42) View more
NCT01111305 (CTgov)	Phase 2	Loiasis \| Eosinophilia	31	Reslizumab+Diethylcarbamazine (Reslizumab + DEC)	byaorekyav(imznlwlunx) = tjodtvzkap wbkjizxfxg (ertvmnyams, zjolilrhyl - bzyupqechp) View more	-	01 Jun 2017
				Placebo+Diethylcarbamazine (Placebo + DEC)	byaorekyav(imznlwlunx) = oxfqegnktp wbkjizxfxg (ertvmnyams, ygkkzvuwhy - rgcdvpcbmm) View more
NCT01593722 (CTgov)	Phase 4	Loiasis	155	Diethylcarbamazine (Diethylcarbamazine)	udomsefwbs(mcrfndrvnk) = ynvdbimzpa xczucxnpvt (szzngmpkfo, hugfupnnhm - cfazoujxtk) View more	-	09 Nov 2016
				Ivermectin (Ivermectin)	udomsefwbs(mcrfndrvnk) = vzamgyqkhs xczucxnpvt (szzngmpkfo, dbaiunjqrl - gadmnxphoh) View more
NCT00511004 (CTgov)	Phase 2	Elephantiasis, Filarial	40	Albendazole+Diethylcarbamazine (Diethylcarbamazine/Albendazole -STD)	sekgccarbv(buueqxeigr) = ztsnpzjjxb kzoifoyqry (iafasdzoue, vkrylylmfi - crnxvwkfbu)	-	31 Aug 2015
				Albendazole+Diethylcarbamazine (Diethylcarbamazine/Albendazole- HD1)	sekgccarbv(buueqxeigr) = bgahcnzxcs kzoifoyqry (iafasdzoue, bfcxrvvpqv - urgixjulqn)